Atrial fibrillation in 2014: based on the updatedguidelines AHA/ACC/HRS

Authors: E.Z. Golukhova, N.I. Bulaeva

Company: A.N. Bakoulev Scientific Center for Cardiovascular Surgery; Rublevskoe shosse, 135, Moscow, 121552, Russian Federation


Keywords: atrial fibrillation antagonists vitamin K novel oral anticoagulants stroke prevention

Download
Full text:  

 

Abstract

Atrial fibrillation (AF) is the most common arrhythmia in linical practice. Number of patients with AF increases every year, primary due to the general aging of the population, as well as the presence of comorbidities. There are huge amount of research carried due to the search for optimal treatment and the most effective management of patients. In this article, we analyzed updated recommendations of the American Heart Association (AHA), American College of Cardiology (ACC) in 2014.

References

1. January C.T., Wann L.S., Alpert J.S. et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 2014. DOI: 10.1016/j.jacc.2014.03.022.
2. Turakhia M., Solomon M.D., Jhaveri M. et al. Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation. Am. Heart J. 2013; 166: 573–80.
3. Kirchhof P., Auricchio A., Bax J. et al. Outcome parameters for trials in atrial fibrillation: executive summary. 2007. Eur. Heart J. 28: 2803–17.
4. Kakkar A.K., Mueller I., Bassand J.-P. et al. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLOS ONE. 2013; 8 (5): e63479.
5. Fox K.A., Eagle K.A., Gore J.M. et al. The Global Registry of Acute Coronary Events, 1999 to 2009 – GRACE. Heart. 2010. 96: 1095–101.
6. Healey J., Oldgren J., Parekh A. et al. Global variations in the 1-year rates of death and stroke in 15,432 patients presenting to the emergency department with atrial fibrillation in 47 countries: The RE-LY AF Registry; 2012; Munich, Germany.
7. Piccini J.P., Holmes D.N., Ollis D.M. et al. Patterns of atrial fibrillation and treatment strategies vary according to provider specialty across community practice settings: findings from the ORBIT-AF Registry. Circulation. 2011; 124: A16415.
8. Knight B.P., Michaud G.F., Strickberger S.A. et al. Electrocardiographic differentiation of atrial flutter from atrial fibrillation by physicians. J. Electrocardiol. 1999; 32: 315–9.
9. Bertaglia E., Zoppo F., Bonso A. et al. Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course and predictors of atrial fibrillation occurrence. Heart. 2004; 90: 59–63.
10. Mason P.K., Lake E., DiMarco J.P. et al. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am. J. Med. 2012; 125: 603–6.
11. Friberg L., Benson L., Rosenqvist M. et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012; 344: e3522.
12. Olesen J.B., Torp-Pedersen C., Hansen M.L. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb. Haemost. 2012; 107: 1172–9.
13. Lip G.Y.H., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart survey on atrial fibrillation. Chest. 2010; 137: 263–72.
14. Hart R.G., Pearce L.A., Aguilar M.I. et al. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann. Intern. Med. 2007; 146: 857–67.
15. Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 160–98.
16. Holbrook A.M., Pereira J.A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 2005; 165: 1095–06.
17. Nieuwlaat R., Prins M.H., Le Heuzey J.Y. et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur. Heart J. 2008; 29: 1181–9.
18. Tulner L.R., Van Campen J.P., Kuper I.M. et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging. 2010; 27: 39–50.
19. Hylek E.M., D’Antonio J., Evans-Molina C. et al. Translating the results of randomized trials into clinical practice. The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006; 37: 1075–80.
20. Broukhim M., Halperin J.L. Stroke prevention in the high-risk atrial fibrillation patient: medical management. Curr. Cardiol. Rep. 2011; 13: 9–17.
21. Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur. Heart J. 2005; 26: 2422–34.
22. Zimetbaum P.J., Thosani A., Yu H.T. et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am. J. Med. 2010; 123: 446–53.
23. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139–51.
24. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Newly identified events in the RE-LY trial. N. Engl. J. Med. 2010; 363 (19): 1875–6.
25. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365: 883–91.
26. Huisman M.V. Results of the 1st Phase of the International GLORIA-AF Registry Program: Regional Treatment Differences Before the Era of Novel Anticoagulants. Oral Presentation on Wednesday 7 May 2014 at the World Heart Federation’s World Congress of Cardiology Scientific Sessions 2014, Melbourne, Australia.
27. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007; 146: 857–67.
28. Aguilar M., Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst. Rev. 2005.
29. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84: 527–39.
30. Bartus K., Han F.T., Bednarek J. et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J. Am. Coll. Cardiol. 2013; 62: 108–18.

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery